{"id":"astromicin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"fortimicin a","offLabel":[],"synonyms":["astromicin sulfate","astromicin","fortimicin a","Antibiotic KW 1070"],"timeline":[],"brandName":"Fortimicin A","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny factories that make proteins to harm you. Fortimicin A stops these bacterial factories from working by binding to a crucial part of the protein-making machinery.","oneSentence":"Fortimicin A works by inhibiting bacterial protein synthesis.","technicalDetail":"Fortimicin A is a type of aminoglycoside antibiotic that binds to the 30S subunit of the bacterial ribosome, thereby inhibiting the initiation complex formation and preventing the translation of mRNA into protein."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/250","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ASTROMICIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:50:32.177923","biosimilars":[],"competitors":[],"genericName":"astromicin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"7JHD84H15J","CHEBI":"CHEBI:37923","INN_ID":"4904","UMLSCUI":"C0060685","ChEMBL_ID":"CHEMBL3084803","KEGG_DRUG":"D01881","PUBCHEM_CID":"5284517","SECONDARY_CAS_RN":"72275-67-3","MESH_SUPPLEMENTAL_RECORD_UI":"C023384"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.0 hours","clearance":"1.37 mL/min/kg","volumeOfDistribution":"0.23 L/kg"},"publicationCount":56,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fortimicin A, also known as Astromicin, is a small molecule antibiotic originally developed by Merck & Co. Its commercial status is currently unknown, and it is not FDA-approved for any indications. The target and drug class of Fortimicin A are also unknown. It has a half-life of 2.0 hours, but its bioavailability and off-patent status are not documented. Further research is needed to understand its mechanism of action and potential clinical applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}